Apogee Therapeutics (APGE) Accumulated Expenses (2022 - 2026)

Apogee Therapeutics (APGE) has reported Accumulated Expenses for 5 consecutive years, with $28.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 7.68% year-over-year to $28.6 million; the TTM figure through Mar 2026 stood at $28.6 million (up 7.68% YoY), while the FY2025 annual figure was $23.2 million, down 4.43% from the prior year.
• Accumulated Expenses improved to $28.6 million in Q1 2026 per APGE's latest filing, from $23.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $29.6 million in Q3 2025 and bottomed at $2.2 million in Q3 2023.
• Historically, Accumulated Expenses has averaged $19.3 million across 5 years, with a median of $21.8 million in 2025.
• Annual changes were most pronounced in 2024 — Accumulated Expenses surged 1139.44% — and 2025, when it dropped 4.43%.
• Apogee Therapeutics' Accumulated Expenses stood at $9.6 million in 2022, then soared by 81.07% to $17.3 million in 2023, then soared by 40.09% to $24.3 million in 2024, then declined by 4.43% to $23.2 million in 2025, then grew by 23.28% to $28.6 million in 2026.
• Business Quant data shows APGE's Accumulated Expenses at $28.6 million in Q1 2026, $23.2 million in Q4 2025, and $29.6 million in Q3 2025.